Why Is Pacira Pharmaceuticals Stock (PCRX) Up 44% Today?
Pacira Pharmaceuticals stock rallied over 44% on Thursday alongside news of a merger agreement with Viatris.
Pacira Biosciences Inc. (PCRX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Leucadia National Ian Cumming And Joseph Steinberg | 427,660 | $10,712,883 | +16% | 0.08% |
| 2. | 1,949,000 | $1,929,492 | -72% | 0.01% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.25 | 1,512 | $20,034.00 | 10,142 | 2024-08-16 | Filing | |
| $12.81 | 1,000 | $12,810.00 | 17,552 | 2024-08-16 | Filing | |
| $12.90 | 2,000 | $25,800.00 | 7,230 | 2024-08-14 | Filing | |
| $12.10 | 8,264 | $99,994.40 | 107,784 | 2024-08-12 | Filing | |
| $12.01 | 3,400 | $40,834.00 | 8,630 | 2024-08-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.32 | 6,000 | $217,920.00 | 62,284 | 2026-10-08 | Filing | |
| $23.23 | 3,040 | $70,619.20 | 216,384 | 2026-08-17 | Filing | |
| $23.50 | 6,115 | $143,702.50 | 62,284 | 2026-06-11 | Filing | |
| $22.27 | 10,259 | $228,467.93 | 167,062 | 2026-06-04 | Filing | |
| $25.16 | 12,941 | $325,595.56 | 105,341 | 2026-04-23 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 88,806,000 | $87,010,947 | 1.78% | |
| 2. | 2,271,610 | $56,905,588 | 0.01% | |
| 3. | 624,805 | $15,651,365 | 2.71% | |
| 4. | 11,500,000 | $11,307,114 | 1.04% | |
| 5. | 352,738 | $8,836,087 | 1.84% |
News See All
15 Best Micro and Small Cap Stocks to Buy According to Jim Simons' Renaissance Technologies
In this article, we will discuss the 15 Best Micro and Small Cap Stocks to Buy According to Jim Simons' Renaissance Technologies.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2026 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2026 Earnings Call Transcript April 30, 2026Pacira BioSciences, Inc. beats earnings expectations. Reported EPS is $0.6, expectations were $0.548.
7 Best Small-Cap Drug Manufacturing Stocks to Buy According to Hedge Funds
In this article, we will take a look at some of the small-cap drug manufacturing stocks that are highly favored by hedge funds.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2025 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2025 Earnings Call Transcript February 26, 2026Pacira BioSciences, Inc. misses on earnings expectations. Reported EPS is $0.57 EPS, expectations were $0.85.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2025 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2025 Earnings Call Transcript November 7, 2025 Operator: Good day, and thank you for standing by.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2025 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2025 Earnings Call Transcript August 6, 2025 Operator: Good day, and thank you for standing by.
Pacira BioSciences Gene Therapy Shows Sustained Knee Osteoarthritis Improvement
Pacira BioSciences Inc. (NASDAQ:PCRX) is one of the most undervalued small-cap stocks to buy according to analysts.
11 Most Undervalued Small-Cap Stocks to Buy According to Analysts
On July 2, Joe Amato, President and Chief Investment Officer at Neuberger Berman, joined 'Squawk Box' on CNBC to discuss the latest market trends.
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2025 Earnings Call Transcript
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2025 Earnings Call Transcript May 8, 2025Pacira BioSciences, Inc. beats earnings expectations. Reported EPS is $0.62, expectations were $0.57.
Hedge Fund Resource Center